Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LeMaitre VascularLMAT +0.78%100 Median PS Value is $76.04 as of Aug. 07, 2026, which is 4565% above its 10-year median of 1.63. GuruFocus rates LMAT with a GF Score™ of 100/100 and a GF Value™ of $95.26 (Modestly Undervalued). Among 332 Medical Devices & Instruments companies, LeMaitre Vascular ranks worse than 79.22% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for LeMaitre Vascular's Median PS Value or its related term are showing as below:
LMAT'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 1.05 Med: 1.63 Max: 4.18
Current: 1.07
During the past 13 years, the highest Price to Median PS Value of LeMaitre Vascular was 4.18. The lowest was 1.05. And the median was 1.63.
LMAT's Price-to-Median-PS-Value is ranked worse than 79.22% of 332
companies
in the Medical Devices & Instruments industry
Industry Median: 0.71
vs LMAT: 1.07
LeMaitre Vascular (NAS:LMAT) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
LeMaitre Vascular's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
81.45
/
76.04
=
1.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LeMaitre Vascular Median PS Value Related Terms
LeMaitre Vascular Median PS Value Historical Data
* Premium members only.
The historical data trend for LeMaitre Vascular's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LMAT vs PLSE, XRAY, ATRC: Median PS Value Comparison
For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LeMaitre Vascular Price-to-Median-PS-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where LeMaitre Vascular's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 6.8703.
LeMaitre Vascular's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.068.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LeMaitre Vascular (LMAT) has a Median PS Value of $76.04 as of Aug. 07, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on LeMaitre Vascular and its competitors. This is 4565% above median its historical median of 1.63. Over the past decade, LeMaitre Vascular's Median PS Value has ranged from 1.05 to 4.18. According to the industry distribution chart, LeMaitre Vascular ranks #263 out of 332 companies in the Medical Devices & Instruments industry, placing it in the top 79.2%.
Is LeMaitre Vascular's Median PS Value too high?
LeMaitre Vascular's current Median PS Value of $76.04 is 4565% above median its 10-year median of 1.63. Over the past 10 years, this metric has ranged from a low of 1.05 to a high of 4.18. The Medical Devices & Instruments industry median Median PS Value is 0.71. LeMaitre Vascular's value of $76.04 is 10609.9% above this industry median. Based on the distribution chart, LeMaitre Vascular ranks #263 out of 332 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, LeMaitre Vascular has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's Median PS Value compare to PLSE and XRAY?
According to the Medical Devices & Instruments industry distribution chart, LeMaitre Vascular ranks #263 out of 332 companies for Median PS Value. This places LeMaitre Vascular in the lower half of its industry. The industry median Median PS Value is 0.71. LeMaitre Vascular's value of $76.04 is 10609.9% above this benchmark. Historically, LeMaitre Vascular's own Median PS Value has ranged from 1.05 to 4.18 over the past decade. While the company's 10-year median is 1.63 vs. the industry median of 0.71, LeMaitre Vascular has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Devices & Instruments company?
The median Median PS Value among Medical Devices & Instruments companies is 0.71, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LeMaitre Vascular's current Median PS Value of $76.04 is 10609.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on LeMaitre Vascular and its competitors. For the Medical Devices & Instruments industry, the median Median PS Value is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LeMaitre Vascular's current Median PS Value is $76.04, which is 4565% above median its own 10-year median of 1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.26, compared to a current price of $81.45 — trading 14.5% below its estimated fair value. The current Median PS Value is $76.04, which is 4565% above median its 10-year median of 1.63 and 10609.9% above the Medical Devices & Instruments industry median of 0.71. LeMaitre Vascular's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current Median PS Value is $76.04 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LeMaitre Vascular (LMAT) Overvalued in 2026?
Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued.
The current stock price of $81.45 is trading 14.5% below its estimated GF Value™ of $95.26.
GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.
Key valuation signals for LMAT:
Median PS Value: $76.04 (4565% above median its 10-year median of 1.63)
GF Value™: $95.26 vs. price of $81.45 (14.5% below fair value)
Industry Position: 10609.9% above the Medical Devices & Instruments median (#263 of 332)
No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
100GF Score
Get the complete analysis for LMAT
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMAT has been successfully added to your 
